title: [Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System  Metastases from Non-small Cell Lung Cancer].
abstract: Approximately half of all patients with non-small cell lung cancer (NSCLC) develop central nervous system metastases during the course of their disease which indicate poor prognosis. A part of NSCLC patients demonstrates activating epidermal growth factor receptor gene (EGFR) mutations who represent effectiveness and well tolerance of EGFR-speciﬁc tyrosine kinase inhibitors (TKIs) therapy. Although the systemic efficacy of targeted agents is established, the efficacy of central nervous system (CNS) metastases is not as well characterized. In this article, we review recent data on the use of EGFR inhibitors for treatment of patients with NSCLC and CNS metastases.
authors: The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors: Yinghua
authors: Y
authors: Jin
authors: The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
authors: Tao
authors: T
authors: Xin
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors